HighTide Therapeutics to Present New PSC and NASH Clinical Data at AASLD 2021
Retrieved on:
목요일, 10월 28, 2021
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Fibrosis, Program, UDCA, Astrophysics Strategic Mission Concept Studies, Orphan drug, Weight loss, Central nervous system disease, 2021 Essex County Council election, AASLD, Primary sclerosing cholangitis, Fatty liver disease, Ursodeoxycholic acid, PBC, US, Association, CNS, NAFLD, Fast Track, T2DM, Patient, Liver injury, Roy Taylor (scientist), ALT, Cholestasis, Liver disease, American Association for the Study of Liver Diseases, HighTide, Chronic liver disease, PSC, American Association, Therapy, NASH, Diabetes, Doctor of Philosophy, Berberine, Primary biliary cholangitis, Pharmaceutical industry, Medical imaging, Dietary supplement, HTD1801, HighTide Therapeutics, HTD1801, HIGHTIDE THERAPEUTICS
HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company, announced today the publication of multiple abstracts highlighting positive Phase 2 clinical data with HTD1801 in patients with primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH).
Key Points:
- HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company, announced today the publication of multiple abstracts highlighting positive Phase 2 clinical data with HTD1801 in patients with primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH).
- The data will be presented at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2021, being held virtually November 12-15, 2021.
- We are excited to present new HTD1801 clinical data in both PSC and NASH, said Liping Liu, PhD, Founder and Chief Executive Officer of HighTide.
- HTD1801 has received Fast Track designation from the US FDA for both PSC and NASH, as well as Orphan Drug designation for PSC.